| Symbol | GLSI |
|---|---|
| Name | GREENWICH LIFESCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3992 BLUEBONNET DRIVE,BUILDING 14, STAFFORD, Texas, 77477, United States |
| Telephone | +1 832 819-3232 |
| Fax | — |
| — | |
| Website | https://www.greenwichlifesciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001799788 |
| Description | Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels. Additional info from NASDAQ: |
NASDAQ traded attribute type Financial_Status was changed. Previous value: Delinquent. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Delinquent. New value: Normal.
Read moreNew Form 10-K - Greenwich LifeSciences, Inc. <b>Filed:</b> 2026-06-01 <b>AccNo:</b> 0001493152-26-026651 <b>Size:</b> 5 MB
Read moreGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
Read moreGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
Read moreGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Read moreGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05232916 | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 … | Phase3 | Breast Cancer | Recruiting | 2022-08-11 | 2026-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| GLSI-100 | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| Placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| GLSI-100 | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| Placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| GLSI-100 | BIOLOGICAL | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| Placebo | BIOLOGICAL | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |